Randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis

Imperial College London (UK)0 个研究点目标入组 130 人开始时间: 2012年5月17日最近更新: 2018年2月19日

适应症

试验速览

•1. Cystic fibrosis confirmed by sweat testing or genetic analysis
•2. Males and females aged 12 years and above
•3. Forced expiratory volume in the 1st second (FEV1) between 50 & 90% predicted inclusive (Stanojevic reference equations)
•4. Clinical stability at screening defined by:
•4.1. Not on any additional antibiotics (excluding routine, long-term treatments) for the previous 2 weeks
•4.2. No increase in symptoms such as change in sputum production/colour, increased wheeze or breathlessness over the previous 2 weeks
•4.3. No change in regular respiratory treatments over the previous 4 weeks
•4.4. If any of these apply, entry into the study can be deferred
•5. Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter (as stated in Gene Therapy Advisory Committee [GTAC] guidelines)
•6. If taking regular rhDNase (pulmozyme), is willing and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose (nebulised doses only)
•7. Written informed consent obtained
•8. Permission to inform general practitioner (GP) of participation in study

•1. Infection with Burkholderia cepacia complex organisms, Methicillin-resistant Staphylococcus aureus (MRSA) or M. abscessus
•2. Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds) (nasal cohort only)
•3. Chloride secretory response on nasal PD of > 5 mV (nasal cohort only; will only be known after first measurement)
•4. Acute upper respiratory tract infection within the last 2 weeks (entry can be deferred)
•5. Previous spontaneous pneumothorax without pleurodesis (bronchoscopic subgroup only)
•6. Recurrent severe haemoptysis (bronchoscopic subgroup only)
•7. Current smoker
•8. Significant comorbidity including:
•8.1. Moderate/severe CF liver disease (varices or significant, sustained elevation of transaminases: ALT/ AST>100 IU/l)
•8.2. Significant renal impairment (serum creatinine > 150 mol/l)
•8.3. Significant coagulopathy (bronchoscopic group only)
•9. Receiving second line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations
•10. Pregnant or breastfeeding

发起方

Imperial College London (UK)